Filing Flows › Cryoport (CYRX) › Q2 2026 › vs Q1 2026
Cryoport (CYRX) Q2 2026 vs Q1 2026 (quarter over quarter)
Cryoport's revenue rose $1.2M (+2%) from $47.8M in Q1 2026 to $49.0M in Q2 2026. The biggest changes: Service +$1.1M (+4%); Product +$102K (+0.5%).
Cryoport, Q2 2026: revenue $49.0M (+8% year over year), operating margin -20.5%, net loss $8.3M, operating cash flow $1.1M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| BioLogistics Solutions | $22.4M | $21.7M | $691K | +3% |
| BioStorage/BioServices | $5.6M | $5.2M | $380K | +7% |
| Service | $28.0M | $26.9M | $1.1M | +4% |
| Product | $21.0M | $20.9M | $102K | +0.5% |
| Revenue | $49.0M | $47.8M | $1.2M | +2% |
| Other income, net | $2.3M | −$822K | $3.1M | — |
| Net loss | $8.3M | $10.5M | −$2.3M | -22% |
| Costs & expenses | $59.5M | $58.3M | $1.2M | +2% |
| Operating costs | $59.0M | $57.4M | $1.6M | +3% |
| Income tax | $505K | $108K | $397K | +368% |
| Cost of revenue | $26.1M | $25.9M | $262K | +1% |
| Research & development | $4.9M | $3.9M | $945K | +24% |
| SG&A | $28.0M | $27.6M | $391K | +1% |
| Operating cash sources | $9.4M | $14.3M | −$4.9M | -34% |
| Depreciation & amortization | $6.6M | $6.4M | $187K | +3% |
| Share-based compensation | $2.4M | $2.4M | $7K | +0.3% |
| Working capital & other | $395K | $5.5M | −$5.1M | -93% |
| Net loss absorbed | $8.3M | $10.5M | −$2.3M | -22% |
| Operating cash flow | $1.1M | $3.7M | −$2.6M | -70% |
| Capital expenditures | $9.1M | $10.0M | −$878K | -9% |
| Negative free cash flow (OCF − capex) | $8.0M | $6.2M | $1.7M | +28% |
Questions
How much did Cryoport's revenue grow quarter over quarter in Q2 2026?
Cryoport's revenue rose $1.2M (+2%) from $47.8M in Q1 2026 to $49.0M in Q2 2026.
What drove Cryoport's revenue change in Q2 2026?
Service +$1.1M (+4%); Product +$102K (+0.5%).